Endocrine complications in long-term survivors of childhood cancers

Wassim Chemaitilly and Charles A Sklar

Abstract

Endocrine disturbances are among the most frequently reported complications in childhood cancer survivors, affecting between 20 and 50% of individuals who survive into adulthood. Most endocrine complications are the result of prior cancer treatments, especially radiotherapy. The objective of the present review is to discuss the main endocrine complications observed in this population, including disorders of the hypothalamic–pituitary axis, disorders of pubertal development, thyroid dysfunction, gonadal dysfunction, decreased bone mineral density, obesity, and alterations in glucose metabolism with a special focus on recent findings reported from the Childhood Cancer Survivor Study.

Introduction

Major advances in the care of children diagnosed with cancer have resulted in a significant increase in survival rates over the past 30 years. The improvement in survival rates is attributed to the use of cancer treatments combining surgery, multiagent chemotherapy, and radiotherapy, in addition to remarkable advances in supportive care. Currently, the 5-year survival rate for acute lymphoblastic leukemia (ALL), the most common cancer in childhood, exceeds 80%, while that for Hodgkin’s lymphoma, the most common cancer in adolescence, is generally > 90% (Mariotto et al. 2009).

Approximately 70% of pediatric cancer survivors will develop at least one medical complication or disability by 30 years from diagnosis, most of which can be attributed to their previous cancer treatments (Oeffinger et al. 2006). Over the past decade, there has been a greater awareness of the frequency and spectrum of these complications. This is in large part due to the efforts of the Childhood Cancer Survivor Study (CCSS) cohort, a retrospective cohort exceeding 14 000 individuals treated for cancer during childhood or adolescence at 26 collaborating institutions in the USA and Canada (Diller et al. 2009, Robison et al. 2009). The CCSS continues to generate data on long-term outcomes of survivors of pediatric cancer.

Endocrine disturbances are among the most frequently reported complications in childhood cancer survivors, affecting between 20 and 50% of individuals, and they frequently occur as late effects of cancer treatments (Diller et al. 2009). Individuals exposed to radiotherapy and high doses of alkylating agents (Table 1; e.g. hematopoietic stem cell transplant (HSCT) recipients, survivors of central nervous system (CNS) tumors, and Hodgkin’s lymphoma) are at particularly high risk of developing endocrine complications (Gurney et al. 2003a, Hows et al. 2006). Such treatments can cause direct damage to key endocrine organs such as the hypothalamic–pituitary axis, the thyroid gland, and the gonads; they can also affect bone mass and alter body composition and glucose homeostasis (Table 2). The following review aims at discussing the most common endocrine problems observed in childhood cancer survivors.

Disorders of the hypothalamic–pituitary axis

Childhood cancer survivors are at risk of multiple hormone deficiencies, often presenting as late effects of a therapy-related injury to the hypothalamus and/or the pituitary (Table 3).
GH deficiency

Impaired linear growth resulting in adult short stature occurs frequently in childhood cancer survivors, particularly in individuals treated at a young age. Both endocrine and non-endocrine factors can contribute to growth retardation. Endocrine factors include GH deficiency (GHD), central precocious puberty (CPP), and primary hypothyroidism. The impact of non-endocrine factors falls beyond the scope of this review, and is mainly represented by the direct damage to the growth plate, mainly of the vertebrae, by high-dose radiotherapy, as following total body irradiation (TBI). The result is a skeletal dysplasia where the sitting height is more affected than the standing height (Shalet et al. 1987, Clayton & Shalet 1991a,b, Brauner et al. 1993, Thomas et al. 1993). A direct and lasting impact of high-dose chemotherapy on the growth plate has not been clearly established (Gleeson et al. 2003, Gurney et al. 2003b).

GHD can occur in childhood cancer survivors as the result of a direct insult to the pituitary gland by tumoral expansion or ablative surgery; tumors, such as craniopharyngiomas, germinomas, and optic nerve gliomas, which arise near the region of the hypothalamus and pituitary, produce GHD as a direct result of the tumor or of the surgery required to remove it. More commonly, however, GHD occurs following irradiation of the hypothalamic–pituitary region.

GHD is the most common and frequently the only anterior pituitary deficit to develop after cranial irradiation (Sklar & Constance 1995, Laughton et al. 2008). In a study on children treated for embryonal brain tumors, where therapy involved very high doses of radiation to the hypothalamic–pituitary area (median 44 Gy), the cumulative incidence of GHD was 93% at 4 years (Laughton et al. 2008). The site of the damage caused by irradiation is more frequently the hypothalamus, which is more sensitive to irradiation than the pituitary, and can be affected by low doses of irradiation (i.e. 18 Gy of conventional fractionated radiotherapy; Costin 1988, Oglivy-Stuart et al. 1994). The pituitary gland itself appears to be damaged only at higher doses of irradiation (Costin 1988).

GHD following the irradiation of the hypothalamic–pituitary region occurs in a time- and dose-dependent fashion, i.e. the higher the dose of radiation and the longer the interval from treatment, the greater the risk (Clayton & Shalet 1991a,b). Thus, GHD can be observed within 5 years of external beam radiation when the doses exceed 30 Gy (Laughton et al. 2008). However, following lower doses, such as 18–24 Gy, GHD may not become evident for 10 or more years (Brennan et al. 1998). The use of TBI in children treated with HSCT has been associated with GHD, which may occur years after the completion of all treatment modalities (Sklar 1997). Radiation-induced GHD is usually permanent; some authors nevertheless recommend retesting patients for GHD after the completion of linear growth before considering treatment with GH through adulthood (Holm et al. 1996, Couto-Silva et al. 2000, Growth Hormone Research Society 2000, Gleeson et al. 2004).

The effects of chemotherapy on the GH–insulin-like growth factor 1 (IGF1) axis are not as well established as those of radiotherapy. Growth failure and abnormal GH stimulation test results have been reported in a small number of patients treated with the combination of cyclophosphamide and busulfan prior to HSCT (Bakker et al. 2004). In one study involving 800 survivors treated with chemotherapy alone, linear growth deceleration was noted in 31 individuals, 15 of whom were diagnosed with GHD (Rose et al. 2004).

In the absence of a ‘gold standard’ diagnostic test for GHD, establishing the diagnosis can be difficult in childhood cancer survivors. The diagnosis is based on the convergence of clinical features and laboratory results. GHD should be suspected in patients with a decreased growth velocity observed over a 6-month time interval (Reiter & Rosenfeld 2003). Measurement of the sitting height in patients who received irradiation to the spine is helpful for the diagnosis and monitoring of radiation-induced skeletal dysplasia (Clayton & Shalet 1991a,b). Pubertal staging is important as concurrent precocious puberty can mask the clinical signs of GHD with seemingly normal growth rates owing to the inappropriate secretion of sex steroids. Body weight and body mass index (BMI) are important markers of nutritional status that can influence linear growth.

GH stimulation tests rely on the measurement of the maximum value of GH over a 2 h time period

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Chemotherapeutic agents associated with germ cell damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating agents</td>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td></td>
<td>Ifosfamide</td>
</tr>
<tr>
<td></td>
<td>Procarbazine</td>
</tr>
<tr>
<td></td>
<td>Busulfan</td>
</tr>
<tr>
<td></td>
<td>Melphalan</td>
</tr>
<tr>
<td></td>
<td>Thiotepa</td>
</tr>
<tr>
<td>Nitrosoureas</td>
<td>BCNU (carmustine)</td>
</tr>
<tr>
<td></td>
<td>CCNU (lomustine)</td>
</tr>
<tr>
<td></td>
<td>Cisplatin</td>
</tr>
</tbody>
</table>

*W Chemaitilly and C A Sklar: Endocrine complications following cancer*
following the administration of a pharmacologic agent known to increase GH secretion (or secretagogue). Although widely used, GH stimulation tests are non-physiologic and often yield non-reproducible results. Failing two stimulation tests using two different secretagogues is generally required for the diagnosis of GHD. Stimulation tests incorporating the insulin tolerance test are believed to be the most reliable, while stimulation tests using arginine combined with GHRH lack sensitivity in individuals treated with radiotherapy (Lissett et al. 2001, Darzy et al. 2003, Björk et al. 2005). Failing one stimulation test was considered enough in patients who received irradiation to the hypothalamus and/or pituitary in the consensus guidelines published by the Growth Hormone Research Society (2000). In GH frequent sampling studies, spontaneous GH secretion is assessed by obtaining multiple blood samples every 20 min over a 12–24 h period. More frequently, the samples are drawn only at night, during sleep (overnight sampling). Frequent sampling appears to be more reliable than GH stimulation tests, but is labor intensive and is available only in a few academic centers (Chemaitilly et al. 2003). IGF1 and IGFBP3 levels are not reliable indicators of the GH status following cranial irradiation or in cases of a CNS lesion as patients with documented hypothalamic/pituitary injury due to irradiation or tumoral expansion as the levels of this growth factors can be in the normal range, despite the presence of GHD (Sklar et al. 1993, Weinzimer et al. 1999).

Contemporary GH replacement regimens have been shown to improve final height prospects in childhood cancer survivors with GHD (Adan et al. 2000, Gleeson et al. 2003). Younger bone age at the beginning of GH replacement and higher doses of GH positively

### Table 2: Endocrine complications and therapy-related risk factors

<table>
<thead>
<tr>
<th>System</th>
<th>Complication</th>
<th>Therapy-related risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linear growth</td>
<td>Skeletal dysplasia</td>
<td>Radiotherapy to the spine. Younger the age and higher the dose, greater the risk</td>
</tr>
<tr>
<td></td>
<td>GH deficiency</td>
<td>Surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cranial radiotherapy</td>
</tr>
<tr>
<td>Puberty</td>
<td>Precocious puberty</td>
<td>Cranial radiotherapy</td>
</tr>
<tr>
<td>Testes</td>
<td>Hypogonadotrophic hypogonadism</td>
<td>Cranial radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Leydig cell dysfunction</td>
<td>Alkylating agents</td>
</tr>
<tr>
<td></td>
<td>Germ cell dysfunction</td>
<td>Radiotherapy to the testes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alkylating agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy to the testes.</td>
</tr>
<tr>
<td>Ovaries</td>
<td>Acute ovarian failure</td>
<td>Alkylating agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy to the ovaries</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alkylating agents</td>
</tr>
<tr>
<td>Adrenals</td>
<td>ACTH deficiency</td>
<td>Radiotherapy to the ovaries</td>
</tr>
<tr>
<td>Thyroid</td>
<td>TSH deficiency</td>
<td>Direct insult (surgery, tumoral expansion)</td>
</tr>
<tr>
<td></td>
<td>Primary hypothyroidism</td>
<td>Cranial radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Primary hyperthyroidism</td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td>Autoimmune disease</td>
<td>TBI</td>
</tr>
<tr>
<td></td>
<td>Neoplasms</td>
<td>131I-MIBG and 131I-labeled monoclonal antibody</td>
</tr>
<tr>
<td>Bone</td>
<td>Osteoporosis</td>
<td>Cranial radiotherapy</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Obesity</td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TBI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>131I-MIBG and 131I-labeled monoclonal antibody</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thyroid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TSH deficiency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neoplasms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TBI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>131I-MIBG and 131I-labeled monoclonal antibody</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary hyperthyroidism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neoplasms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TBI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>131I-MIBG and 131I-labeled monoclonal antibody</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary hyperthyroidism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neoplasms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TBI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>131I-MIBG and 131I-labeled monoclonal antibody</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary hyperthyroidism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neoplasms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy (local or scatter)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TBI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>131I-MIBG and 131I-labeled monoclonal antibody</td>
</tr>
</tbody>
</table>

131I-MIBG, iodine-131-metaiodobenzylguanidine; HSCT, hematopoietic stem cell transplantation.
correlated with a better final height outcome in a report from the CCSS, supported by final height data on 183 childhood cancer survivors treated with GH (Brownstein et al. 2004). In contrast, children previously treated with radiation doses O20 Gy to the spine respond less well to GH. For the subset of patients with both GHD and precocious puberty, the combination of GH and a GnRH agonist that temporarily suppresses puberty appears to improve final height outcome (Gleeson et al. 2003).

Given the anti-apoptotic, mitogenic, and proliferating properties of GH and IGF1, the safety of the use of GH in childhood cancer survivors has been the subject of large-scale studies. The studies assessing the risk of tumor recurrence, largely confined to brain tumor survivors treated with GH, have consistently reported no increased risk associated with GH replacement therapy (Swerdlow et al. 2000, Packer et al. 2001, Sklar et al. 2002). There was no evidence for an increased risk of disease recurrence or death following GH replacement therapy in a report from the CCSS on 361 GH-treated individuals, including 122 survivors of acute leukemia and 43 survivors of soft tissue sarcomas (Sklar et al. 2002). However, the data suggested that treatment with GH may slightly increase the risk of a secondary solid tumor, especially in survivors of acute leukemia. (Sklar et al. 2002). These suspicions were confirmed in an updated analysis of the same cohort after an additional 32 months of follow-up, in which the relative risk of survivors treated with GH developing a second neoplasm was 2.15 (95% confidence interval (CI) 1.3–3.5, P<0.002; Ergun-Longmire et al. 2006). In this updated analysis, meningiomas were the most common second neoplasms that were observed in survivors treated with GH. There was no association between dose and duration of GH therapy and this risk, and there was no difference in the risk of death in survivors treated with GH compared with survivors not treated so (Ergun-Longmire et al. 2006). Cancer survivors treated with GH may be at a higher risk of developing slipped epiaphyses compared with children treated with GH for idiopathic GHD (Blethen & Rundle 1996).

Adult GHD is now an established indication for GH therapy, given its association with metabolic derangements, such as increased body fat, raised plasma lipids, and decreased bone density and reduced quality of life (Link et al. 2004). Treatment with GH in adult survivors of childhood cancer seems to have a greater impact on quality of life and to result in more modest, although significant, improvements in the metabolic parameters (Murray et al. 2002, Mukherjee et al. 2005, Follin et al. 2006).

### Disorders of LH/FSH

**Central precocious puberty**

Precocious puberty is defined as the onset of puberty before the age of 8 years in girls and 9 years in boys. CPP is due to the premature activation of the hypothalamic–pituitary–gonadal axis, and in girls, it

---

**Table 3** Therapy-related complications affecting the hypothalamus/pituitary

<table>
<thead>
<tr>
<th>Complication</th>
<th>Therapy-related risks</th>
<th>Relationship to time, dose to the pituitary/hypothalamus when applicable, and available cumulative incidence data</th>
</tr>
</thead>
<tbody>
<tr>
<td>GH deficiency</td>
<td>Surgery</td>
<td>Immediate effect</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy to hypothalamic–pituitary region</td>
<td>Doses &gt;30 Gy: effect by 5 years following exposure. Cumulative incidence ~90% over 4 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Doses 18–24 Gy: effect may not become evident for &gt;10 years following the exposure</td>
</tr>
<tr>
<td>Precocious puberty</td>
<td>Radiotherapy to hypothalamic–pituitary region</td>
<td>Doses 18 Gy and above. Increased risk for girls &lt;5 years with incidence of 10–20%</td>
</tr>
<tr>
<td>Hypogonadotropic hypogonadism</td>
<td>Radiotherapy to hypothalamic–pituitary region</td>
<td>Doses &gt;30 Gy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Incidence 10–20% doses &gt;50 Gy</td>
</tr>
<tr>
<td>ACTH deficiency</td>
<td>Surgery</td>
<td>Immediate effect</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy to hypothalamic–pituitary region</td>
<td>Doses &gt;30 Gy; possible cumulative incidence 38% over 4 years</td>
</tr>
<tr>
<td>TSH deficiency</td>
<td>Glucocorticoids</td>
<td>Effect dose and duration dependent</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy to hypothalamic–pituitary region</td>
<td>Doses &gt;30 Gy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cumulative incidence 23% over 4 years for patients treated with doses &gt;42 Gy</td>
</tr>
</tbody>
</table>
can lead to the early onset of menstrual cycles, with menses occurring before the age of 10 years (Sigurjonssdottir & Hayes 1968). Cranial irradiation at both lower doses (18–35 Gy) and higher doses (>35 Gy) is associated with the development of CPP, by presumably disrupting inhibitory cortical influences (Brauner et al. 1984, Constine et al. 1993, Oberfield et al. 1996, Chow et al. 2008, Armstrong et al. 2009). In contrast, radiation doses >50 Gy are also associated with hypogonadotropic hypogonadism within the context of combined hormonal pituitary deficiencies (Lam et al. 1991, Constine et al. 1993, Armstrong et al. 2009). Risk factors associated with CPP following hypothalamic irradiation include female sex, young age at treatment, and increased BMI (Ogilvy-Stuart & Shalet 1995, Oberfield et al. 1996).

In a report from the CCSS on CNS tumor survivors, early menarche (defined by the onset of menstrual cycles before 10 years of age) occurred in 14.5% of girls with a history of radiation to the hypothalamus–pituitary area, which was significantly more common than what was observed in siblings. Risk factors for early menarche included radiation before the age of 5 years or with doses >50 Gy (Armstrong et al. 2009). The age-inappropriate sex steroid secretion can cause rapid bone age progression and further reduce the growth potential of children, most of whom carry additional risk factors for growth failure such as GHD and radiation-induced skeletal dysplasia.

In girls, precocious puberty is best characterized by the onset of sustained breast development before the age of 8 years (Sigurjonssdottir & Hayes 1968). In boys, testicular volume, used to assess the onset of pubertal development in the general population, may not be a reliable indicator of puberty in childhood cancer survivors as chemotherapy and radiation can damage the seminiferous tubules, resulting in testes that are inappropriately small for a given stage of puberty. Thus, clinicians should be alerted by the early onset of other secondary sexual characteristics (e.g. pubic hair) prior to the age of 9 years. One of the first signs of pubertal development is an increase in the growth rate. In children who also are likely to have GHD, this may result in falsely reassuring ‘normal’ growth velocity, as mentioned previously.

Skeletal maturation can be assessed using the standard bone age (X-ray examination of the left wrist and hand) in order to estimate the individual’s skeletal age (Greulich & Pyle 1959). Advancement of the bone age more than 2 s.d. for chronological age is a consistent finding in children with precocious puberty. In girls with CPP, uterine growth on the pelvic ultrasound is a sign of estrogen stimulation, and is an earlier finding than bilaterally enlarged ovaries. Gonadotropin secretion is best assessed using the GnRH or GnRH agonist stimulation tests. An ample LH response, greater than the FSH response, indicates a pubertal pattern. The plasma estradiol levels in girls and testosterone levels in boys are also important indicators of pubertal development.

Delaying the progression of puberty in childhood cancer survivors with CPP results in the stabilization of the advancement of the bone age, and hence has been shown to improve the statural outcome, especially when contemporary regimens for GH replacement are used concurrently to treat GHD (Gleeson et al. 2003). Long-acting formulations of GnRH agonists are currently the treatment of choice when it is deemed clinically desirable to postpone pubertal progression.

**Hypogonadotropic hypogonadism**

Insufficient LH and FSH secretion has been reported in childhood cancer survivors. Deficits of LH and FSH secretion following irradiation of the hypothalamic–pituitary region occur less often than GHD, and generally only occur following doses to the sellar region, >30 to 40 Gy (Sklar & Constine 1995, Relander et al. 2000, Byrne et al. 2004, Armstrong et al. 2009, Green et al. 2009). In a report from the CCSS on survivors of childhood CNS tumors, late menarche (defined by the onset of menstrual cycles after 16 years of age) was used as a marker for hypogonadotropic hypogonadism, given that few patients were additionally exposed to alkylating agents (Table 1), known for their ovarian toxicity. In this study, late menarche was observed in 10.6% of the survivors, and was associated with doses of radiation >50 Gy, treatment after 10 years of age, and the diagnosis of medulloblastoma (Armstrong et al. 2009). In a recent report from the CCSS, female survivors with a history of exposure to doses of radiation >30 Gy to the hypothalamic–pituitary area were less likely to experience a pregnancy (Green et al. 2009).

In female ALL survivors, ‘subtle’ defects of gonadotropin secretion following radiation doses in the 18–24 Gy range have been described (Bath et al. 2001, Byrne et al. 2004); additional long-term follow-up data will provide a better sense of the ultimate effect of these lower doses of cranial irradiation on hypothalamic–pituitary–gonadal function. It is unclear whether chemotherapy alone can directly alter gonadotropin secretion (Bakker et al. 2004).
**ACTH deficiency**

Apart from transient ACTH deficiency resulting from chronic suppression due to the prolonged use of pharmacologic doses of glucocorticoids, ACTH deficiency in childhood cancer survivors is relatively uncommon. It can be observed either as a result of direct tumoral impingement on the hypothalamic–pituitary axis and surgery in that region, or following high-dose (>30 Gy) radiation (Rose et al. 2005, Patterson et al. 2009). In a study on children receiving treatment for CNS embryonal tumors that included high doses of radiation to the hypothalamic–pituitary area (median dose 44 Gy), the 4-year cumulative incidence of ACTH deficiency was 38% (Laughton et al. 2008). As different investigators use different methods to establish a diagnosis of ACTH deficiency, comparison between studies can be difficult.

**TSH deficiency**

TSH deficiency, resulting in central hypothyroidism, occurs less often than GHD and CPP following the irradiation of the hypothalamic–pituitary area. It has been reported following doses >30 to 40 Gy (Sklar & Constine 1995, Rose et al. 1999, Schmiegelow et al. 2003, Laughton et al. 2008). In a study on children receiving treatment for CNS embryonal tumors resulting in high doses of radiation to hypothalamus–pituitary area, the cumulative incidence of TSH deficiency was 23% at 4 years with a significant risk for patients with doses to the hypothalamic–pituitary area above 42 Gy (Laughton et al. 2008). In contrast, a report by the CCSS on survivors of ALL suggested that cranial radiotherapy (doses <30 Gy) alone was insufficient to induce central hypothyroidism (Chow et al. 2009). There are few reports in the literature on the contribution of chemotherapy to the development of central hypothyroidism in childhood cancer survivors. Apart from one report suggesting a high incidence of patients with subtle TSH deficiency, as evidenced by the lack of nocturnal surge of TSH, most authors concur on the lack of association between chemotherapy and central hypothyroidism (Sanders et al. 1986, Van Santen et al. 2003, Bakker et al. 2004, Chow et al. 2009).

**Hyperprolactinemia**

High-dose hypothalamic irradiation, in the range of 50 Gy or greater, can be associated with hyperprolactinemia. Up to 75% of adult patients and 30% of pediatric patients had elevated baseline prolactin levels in a report on 32 patients who received high-dose cranial radiotherapy (39.6–70.2 Gy, with a mean 53.6 Gy) as treatment for brain tumors (Constine et al. 1993).

**Disorders of the thyroid**

Abnormalities of the thyroid gland are among the most frequent endocrine complications that are observed in childhood cancer survivors (Table 4). Early recognition and treatment of thyroid dysfunction are crucial in this population, given the importance of thyroid hormones for normal growth and development during childhood.

**Therapy-induced primary hypothyroidism**

Primary hypothyroidism is the most frequently observed thyroid disorder following exposure of the gland to radiation. This exposure can occur in individuals treated with the following types of radiation: neck/mantle irradiation for Hodgkin’s lymphoma; craniospinal irradiation for brain tumors; or TBI for cytoreduction before HSCT (Chin et al. 1997, Brennan et al. 1998, Sklar et al. 2000a,b, Van Santen et al. 2003, Chow et al. 2009, Laughton et al. 2008). Primary hypothyroidism has also been described in individuals treated with radiolabeled agents such as 131I-metaiodobenzylguanidine (Picco et al. 1995) and 131I-labeled monoclonal antibody for neuroblastoma (Laverdière et al. 2005). Chemotherapy alone does not seem to be associated with an increased incidence of primary hypothyroidism (Metzger et al. 2006a,b, Chow et al. 2009). The prevalence of hypothyroidism is primarily determined by the total dose of radiation to the thyroid and by the duration of follow-up (Fig. 1). Additional risk factors for developing hypothyroidism include female gender, white race, and age >15 years at the time of diagnosis (Sklar et al. 2000a,b, Metzger et al. 2006a,b). In a large study from the CCSS on young adult survivors of Hodgkin’s lymphoma, a cumulative incidence of hypothyroidism of 28% was observed; for those treated with doses >45 Gy, there was a 50% incidence of hypothyroidism 20 years after diagnosis (Sklar et al. 2000a,b). By contrast, in a study from the CCSS on thyroid dysfunction in ALL survivors, the cumulative incidence of hypothyroidism was only 1.6%, which was, nonetheless, significantly higher than that in the cohort of siblings (Chow et al. 2009). Survivors who received >20 Gy cranial radiation plus any spinal radiotherapy had the highest risk for developing hypothyroidism. Interestingly, the time interval between the diagnosis of cancer and that of hypothyroidism was notably more prolonged.
in survivors of ALL (>10 years) compared with survivors of Hodgkin’s disease (Chow et al. 2009). As hypothyroidism can occur more than 25 years following the completion of cancer treatments, it is imperative that individuals at risk undergo lifelong surveillance.

Therapy-induced hyperthyroidism

Hyperthyroidism occurs less frequently than hypothyroidism in childhood cancer survivors. It is diagnosed most often following external beam radiation to the neck for Hodgkin’s lymphoma. In a large study from the CCSS that included more than 1700 survivors of Hodgkin’s lymphoma, survivors were eight times more likely to develop hyperthyroidism compared with siblings (Sklar et al. 2000a,b). The only identified risk factor for the development of hyperthyroidism was exposure to doses >35 Gy to the thyroid (Sklar et al. 2000a,b). In a recent CCSS report on thyroid dysfunction in ALL survivors, the cumulative incidence of hyperthyroidism was 0.6%, which was much lower than the incidence of hypothyroidism but still higher than the incidence observed in the control population of siblings. The greatest risk was seen in those in whom the absorbed dose to the thyroid exceeded 15 Gy (Chow et al. 2009).

Autoimmune thyroid disease

There are several reports of the occurrence of autoimmune thyroid disease in allogeneic HSCT recipients (Sklar et al. 2001, Au et al. 2005). The adoptive transfer of abnormal clones of T- or B-cells from donor to host could be responsible for these observations. Hypothyroidism with or without a preceding hyperthyroid phase was observed in subjects with positive thyroglobulin autoantibody (Au et al. 2005). Hyperthyroidism with positive TSH receptor autoantibodies has also been reported following allogeneic HSCT (Sklar et al. 2001).

Thyroid neoplasms

The exposure of the thyroid to either direct or scatter (for example, after prophylactic CNS irradiation in patients treated for ALL) radiation is a significant risk factor for thyroid neoplasms, benign and malignant.
Children treated before 10 years of age and/or with doses in the range of 20–29 Gy appear to be at the greatest risk for the development of thyroid cancer. The association between thyroid irradiation and thyroid neoplasms is linear at low doses of radiation, but shows a downward turn at doses above 30 Gy, with a risk that remains, nevertheless, elevated compared with the general population (Sigurdson et al. 2005). In a recent report from the British CCSS, the standardized incidence ratio for thyroid cancer was 18.0 (95% CI 13.4–23.8), with the highest risk being observed in survivors of Hodgkin’s lymphoma (Taylor et al. 2009). The majority of cancers were differentiated carcinomas (i.e. papillary and follicular) with a median latency of 20.8 years, similar to data published from the CCSS (Sklar et al. 2000a, Sigurdson et al. 2005, Taylor et al. 2009).

In general, postirradiation thyroid cancers behave in a non-aggressive fashion, similar to what is observed in de novo thyroid cancers among the young (Acharya et al. 2003). The pathogenesis of radiation-induced thyroid neoplasms is felt to be related to rearrangements of rearranged in transformation–papillary thyroid carcinomas (RET/PTC) gene induced by the exposure to radiation (Boumaer et al. 1997, Elisei et al. 2001). Thyroid neoplasms following radiotherapy may not become evident for many years after exposure to radiation; therefore, all individuals at risk require lifelong follow-up (Sklar et al. 2000a, Acharya et al. 2003, Chow et al. 2009). While thyroid ultrasound screening has been recommended by some groups (Brignardello et al. 2008), it may lead to unnecessary and invasive procedures, and has not been shown to reduce morbidity or mortality in this population (Metzger et al. 2006a, b).

**Gonadal dysfunction**

In addition to the derangements related to gonadotropin secretion, childhood cancer survivors are at risk of gonadal dysfunction related to a direct insult to the testes or ovaries (Table 5).

**Males**

The human testis combines two functions: sex steroid production and sperm production. Although interconnected, these functions are under separate controls. These include a multitude of endocrine, paracrine, and autocrine factors (Griffin & Wilson 1992). In the testis, germ cells ultimately form sperm; Sertoli cells support and nurture the developing germ cells, and are also the site of production of inhibin; and interstitial Leydig cells are responsible for the biosynthesis of testosterone. These three cell types are organized into two functional compartments: germ cells and Sertoli cells form the seminiferous tubules where spermatogenesis takes place, and the network of Leydig cells which are responsible for the production of testosterone. Leydig cells lie in proximity to the basal compartment of the seminiferous tubules, where they can deliver high concentrations of testosterone, which are necessary for normal spermatogenesis. Despite their interconnection, these two functional compartments are affected in different ways by cancer treatments.

**Leydig cell dysfunction**

Treatment-induced Leydig cell failure and testosterone insufficiency are relatively uncommon compared with germ dysfunction and infertility following cancer treatments. Leydig cell failure will result in delayed/arrested puberty and lack of secondary sexual characteristics if it occurs before the onset of puberty. If it occurs following the completion of normal pubertal development, it can result in reduced libido, erectile dysfunction, decreased bone mineral density (BMD), decreased muscle mass, and other metabolic disturbances (Sklar 1999). Raised plasma concentrations of LH combined with low levels of testosterone are characteristic of Leydig cell dysfunction, but these changes may not become apparent until the individual has reached mid-adolescence (Shalet et al. 1985). Thus, it can be very difficult to assess or predict Leydig cell function in the preadolescent males.


By contrast, Leydig cells are more vulnerable to radiation-induced damage. The interpretation of the impact of radiation on Leydig cell function is confounded by the concurrent use of chemotherapy in...
most subjects as well as by the potential effects of the malignancy itself (e.g. testicular relapse in ALL). Leydig cell failure, nevertheless, occurs at doses of radiation higher than those associated with germ cell dysfunction. The likelihood of sustaining radiation-induced Leydig cell failure is directly related to the dose delivered and inversely related to age at treatment (Leiper et al. 1986, Shalet et al. 1989, Sarafoglou et al. 1997). Normal amounts of testosterone are produced by the majority of males who receive 20 Gy fractionated radiation to the testes (Sklar 1999). A dose of 24 Gy of fractionated irradiation as therapy for young males with testicular relapse of ALL is associated with a very high risk for Leydig cell dysfunction. The majority of boys who are prepubertal at the time they receive 24 Gy testicular irradiation will develop Leydig cell failure and require androgen replacement (Shalet et al. 1985, Leiper et al. 1986). Testicular doses in excess of 33 Gy have been associated with Leydig cell failure in 50% of adolescent and young adult men (Izard 1995).

Germ cell dysfunction
The sperm-producing cells are more vulnerable to cancer treatments than Leydig cells, and are frequently impaired by radiotherapy and several types of chemotherapy. Germ cell dysfunction with resultant infertility is often associated with reduced testicular volume, increased FSH concentrations, and reduced plasma concentrations of inhibin B (Lewis & Lee 2009). However, for clinical purposes and counseling, assessing male fertility requires obtaining a sperm count as none of these aforementioned surrogate markers has sufficient specificity or sensitivity to predict outcome for an individual subject (Andreu et al. 2000, Kenney et al. 2001).

The chemotherapeutic agents most commonly associated with impaired male fertility are alkylating agents (Table 1). Impaired fertility occurs in 40–60% of young adult survivors of childhood cancer, and young age at exposure does not seem to be protective, as previously thought (Kenney et al. 2001). A high probability of oligospermia,azoospermia, and infertility is associated with doses of cyclophosphamide greater than 20 g/m². In contrast, many individuals treated with a cumulative dose of 7.5–10 g/m² or less retain normal sperm production (Relander et al. 2000, Kenney et al. 2001). Procarbazine, another alkylating agent commonly used in the treatment of Hodgkin’s lymphoma, has also been shown to induce impaired sperm production in a dose-dependent fashion. Patients with Hodgkin’s lymphoma and who received three mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) cycles alternating with three cycles of doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazin seemed to suffer less testicular damage than patients who received six MOPP cycles (Mackie et al. 1996, van den Berg et al. 2004). Most of the young men treated with the combination of busulfan and cyclophosphamide in preparation for HSCT do appear to sustain damage to their germinal epithelium, with possible recovery for patients treated at lower doses (120 mg/kg for cyclophosphamide and 16 mg/kg for busulfan; Grigg et al. 2000, Anserini et al. 2002).

Impaired sperm production can occur at doses of radiation as low as 0.15 Gy. If the dose is under 1–2 Gy, recovery is common. At doses greater than 2 to 3 Gy, recovery of sperm production is rare (Meistrich et al. 1997). Germ cell dysfunction is present in essentially all males treated with TBI (Sanders et al. 1996). Azoospermia is the rule for patients studied in the first few years after treatment with TBI. Recovery of germ

---

**Table 5 Therapy-related complications affecting the gonads**

<table>
<thead>
<tr>
<th>Complication</th>
<th>Therapy-related risks</th>
<th>Relationship to time, dose to the gonads when applicable, and available cumulative incidence data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Testes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leydig cell dysfunction</td>
<td>Alkylating agents</td>
<td>Generally subclinical. Cumulative incidence 10–57%</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
<td>Doses &gt; 24 Gy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cumulative incidence 50% for doses &gt; 33 Gy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyclophosphamide doses &gt; 10 g/m²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Doses &gt; 0.15 Gy: possible risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Doses &gt; 2 Gy high risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In combination, cumulative risk 40–60%</td>
</tr>
<tr>
<td>Germ cell failure</td>
<td>Alkylating agents</td>
<td>Higher risk for older age at exposure</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
<td>Radiotherapy dose &gt; 20 Gy: cumulative incidence 70%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In combination, cumulative risk 30%</td>
</tr>
<tr>
<td><strong>Ovaries</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute ovarian failure</td>
<td>Alkylating agents</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiotherapy to the ovaries</td>
<td></td>
</tr>
<tr>
<td>Premature menopause</td>
<td>Alkylating agents</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In combination, cumulative risk 40–60%</td>
</tr>
</tbody>
</table>
cell function has occurred rarely and primarily following single-dose irradiation (Sklar et al. 1984, Sanders et al. 1996). Given the high rate of impaired sperm production in survivors, sperm banking should be offered to all adolescent males prior to the initiation of cancer therapy, whenever clinically feasible.

**Females**

The sex steroid-producing cells and oocytes are functionally and structurally interdependent within the ovarian follicle. As a result, when ovarian failure occurs, both sex hormone production and fertility are disrupted (Sklar 1999). Older age is an important risk factor for ovarian failure following childhood cancer and its treatments, given the progressive decline in oocyte reserve with increasing age (Sklar 1999). If ovarian function is lost prior to the onset of puberty, it will result in delayed puberty and primary amenorrhea. If ovarian function is lost during or after pubertal maturation, one generally observes arrested puberty, secondary amenorrhea, and menopausal symptoms (i.e. hot flashes and vaginal dryness). Women who experience premature loss of estrogen production are also predisposed to developing osteoporosis and coronary artery disease (Aisenberg et al. 1998). Increased plasma concentrations of gonadotropins, especially FSH, and reduced levels of estradiol are typically found in the adolescent and young adults with ovarian failure. These markers cannot be used in younger children as gonadotropins are often normal despite ovarian damage (Carr 1992).

The loss of ovarian function owing to exposure to cancer treatments can occur either early (during or immediately following the completion of treatment with the so-called acute ovarian failure (AOF)), or many years after the completion of cancer therapy but prior to the age of 40 years (the so-called premature menopause; Chemaitilly et al. 2006, Sklar et al. 2006). The incidence of AOF was 6.3% in a report from the CCSS (Chemaitilly et al. 2006), whereas the cumulative incidence of premature menopause was 8%, ten times higher than that observed in sibling controls (Sklar et al. 2006).

Owing to a greater follicular reserve, the ovaries of prepubertal girls are more resistant to chemotherapy-induced damage when compared with the ovaries of adults (Carr 1992, Grigg et al. 2000, Chemaitilly et al. 2006; Fig. 2). Nevertheless, certain chemotherapeutic agents, especially alkylating agents (Table 1), when given at high doses can cause ovarian failure, even in younger subjects (Rivkees & Crawford 1988, Wallace et al. 1989b, Chemaitilly et al. 2006, Sklar et al. 2006). In a report from the CCSS, older age at treatment and exposure to procarbazine at any age and to cyclophosphamide at ages 13–20 years were independent risk factors for AOF (Chemaitilly et al. 2006). Females who receive high-dose myeloablative therapy with alkylating agents such as busulfan, melphalan, and thiotepa in preparation for HSCT are at high risk of developing ovarian failure (Michel et al. 1997). This has been observed in patients treated both before and after pubertal development. Recovery of function has been recorded only rarely, but the follow-up time has been relatively brief for most of the patients (Thibaud et al. 1998). However, the majority of prepubertal girls and adolescents receiving standard chemotherapy will fortunately maintain or recover ovarian function during the immediate posttreatment period (Horning et al. 1981, Hudson et al. 1993, Sklar 1999). Histologic examination of ovarian tissue in prepubertal and postpubertal girls treated for solid tumors or leukemia has nevertheless revealed a decreased number of ovarian follicles and inhibition of follicular growth compared with age-matched controls (Himmelstein-Braw et al. 1978, Larsen et al. 2003). Thus, it is not surprising that among women who do retain or recover function following treatment with standard doses of alkylating agents, a subset will experience premature menopause when they reach their 20s and 30s (Byrne et al. 1992, Nasir et al. 1997, Papadakis et al. 1999, Sklar 1999, Sklar et al. 2006).

In a report from the CCSS, female survivors with a history of exposure to high doses of alkylating agents, to lomustine or to cyclophosphamide were less likely to experience a pregnancy when compared with sibling controls (Green et al. 2009). When female childhood
cancer survivors treated with chemotherapy did get pregnant, no adverse pregnancy outcomes were identified in a large study conducted within the framework of the CCSS (Green et al. 2002).

Females receiving abdominal, pelvic, or spinal irradiation are at increased risk of ovarian failure, especially if both ovaries were within the treatment field (Horning et al. 1981, Damwood & Grochow 1986, Hamre et al. 1987, Clayton et al. 1989, Wallace et al. 1989a, Thibaud et al. 1992, Sklar et al. 2006, Chow et al. 2008). However, when ovarian transposition is performed prior to radiotherapy, ovarian function is retained in the majority of young girls and adolescent females (Thibaud et al. 1992, Sklar 1999). While radiation doses of 6 Gy may be sufficient to produce irreversible ovarian damage in women > 40 years of age, doses in the range of 10–20 Gy are needed to induce permanent ovarian failure in the majority of females treated during childhood (Wallace et al. 1989a, Thibaud et al. 1992). In a report from the CCSS, radiation doses to the ovary > 20 Gy were associated with the highest rate of AOF (70%), with higher rates in older individuals (13–20 years) when compared with those who were younger (0–12 years) at the time of treatment (Chemaitilly et al. 2006). Moreover, if radiation is being given in association with alkylating agent chemotherapy, ovarian dysfunction may occur despite the use of lower doses. In a report from the CCSS on premature menopause, while both radiation to the ovaries and exposure to alkylating agents were independent risk factors, the cumulative incidence of premature menopause in individuals treated with both alkylating agents and abdominal–pelvic radiation was in the range of 30% (Sklar et al. 2006). In a report from the CCSS, survivors treated with radiotherapy doses > 5 Gy to the ovaries/uterus were less likely to experience a pregnancy when compared with sibling controls (Green et al. 2009).

The outcome of ovarian function following TBI appears to be determined to a large extent by the age of the patient at the time of irradiation. Approximately 50% of prepubertal girls given fractionated TBI will enter puberty spontaneously and achieve menarche at a normal age (Sarafoglou et al. 1997, Matsumoto et al. 1999). Ovarian failure is seen in essentially all patients who are aged > 10 years at the time they are treated with TBI (Sanders et al. 1988, Matsumoto et al. 1999). Recovery of ovarian function has, nevertheless, been documented in a small number of women who have received TBI (Sanders et al. 1996). These women had increased risks of miscarriage and premature delivery of low-birth weight infants. This can be due to the uterine consequences of TBI (Sanders et al. 1996, Bath et al. 1999, Holm et al. 1999, Matsumoto et al. 1999, Larsen et al. 2004).

Bone density and risk of osteoporosis

Childhood cancer survivors as a group have reduced BMD, and are at an increased risk for osteopenia, osteoporosis, and fractures (Aisenberg et al. 1998, Sala & Barr 2007, Wasilewski-Masker et al. 2008). This is the result of mainly three factors: the primary disease itself (Crofton et al. 1998); exposure to glucocorticoids and other chemotherapeutic agents such as methotrexate (De Boer et al. 1994, Stanislavevic & Babcock 1997, Brennan et al. 1999, Sala & Barr 2007, Wasilewski-Masker et al. 2008); and the hormonal deficiencies associated with cancer and its treatments (and described earlier in the text), GHD and sex hormone deficiencies (Aisenberg et al. 1998, Nysom et al. 2000, Sala & Barr 2007, Wasilewski-Masker et al. 2008). Fractures were shown to occur in up to 39% of children during treatment for ALL (Halton et al. 1996). Although BMD improves after the completion of treatment, childhood cancer survivors remain at an increased risk of osteopenia long term (Thomas et al. 2008, Wasilewski-Masker et al. 2008). Genetic predisposition (such as CRHR1 polymorphisms) may increase the risk of low BMD, especially following exposure to glucocorticoids or methotrexate (Jones et al. 2008).

Subjects deemed at high risk for the development of osteoporosis should undergo periodic bone density studies (Wasilewski-Masker et al. 2008). While dual energy X-ray absorptiometry (DEXA) remains the most widely used tool for measuring BMD, its results should be interpreted according to age, pubertal stage, and height in the pediatric population using T-scores not Z-scores. Failure to take these elements into account may result in an over-diagnosis of osteoporosis during childhood and adolescence (Nysom et al. 2000, Gafni & Baron 2004). Preventive measures (for example, supplementation with calcium and vitamin D, smoking cessation, and weight-bearing exercise) should be encouraged in all individuals with low or borderline BMD. In addition, sex hormone replacement therapy and GH replacement are useful in improving BMD in subjects with known deficiencies.

Overweight, obesity, and disorders of glucose homeostasis

Obesity and being overweight are often observed in survivors of acute leukemia and various brain tumors (Sklar et al. 2000a,b). Risk factors for obesity include
cranial irradiation, female gender, and exposure to dexamethasone. The deleterious effects of dexamethasone on body composition may be temporary (van der Sluis et al. 2002). A report from the CCSS found that cranial radiotherapy > 20 Gy, especially in females treated at a young age (< 4 years), was significantly associated with obesity (i.e. BMI > 30; Oeffinger et al. 2003). In a more recent study that examined change in BMI over time in the same cohort of ALL survivors, female gender, treatment at a young age, and cranial radiotherapy were associated with a more rapid rate of BMI increase (Garmey et al. 2008). Within the CCSS cohort, female survivors with a BMI above 25 kg/m² were more likely to be homozygous for a polymorphism of the leptin receptor (Arg allele at Gln 223 Arg) that has been associated with obesity in the general population than female survivors with a BMI below 25 kg/m². The difference is particularly significant in survivors treated with cranial radiotherapy; females having this particular polymorphism were six times more likely to become obese (Ross et al. 2004). This observation underscores the importance of genetic susceptibility to the toxic effects of the therapeutic exposures routinely used to treat children with cancer (Armenian & Bhatia 2009).

GHD in adulthood has been associated with obesity, and may contribute to the observed changes in body composition in ALL survivors who received high-dose cranial radiotherapy (Talvensaari et al. 1996). Childhood ALL survivors have also been shown to have reduced physical activity, even many years after the completion of cancer therapy, but the contribution of this behavioral factor to the development of obesity remains uncertain (Reilly et al. 1998). Premature adiposity rebound, believed to be a predictor of adult obesity, was also described in childhood ALL survivors, and may partly explain the increased risk for obesity in patients treated at a very young age (< 5 years; Reilly et al. 2001).

Brain tumors developing near the sellar region and their treatments (e.g. surgery and radiation) can also disrupt hypothalamic and pituitary functions and induce states of morbid obesity (Lustig et al. 2003a,b). While a hypothalamic insult has been hypothesized to alter satiety centers and cause hyperphagia, another mechanism involving an increased parasympathetic tone leading to hyperinsulinemia (the latter promoting fat storage) has been suggested as a contributing factor to obesity in these patients. It is with regard to the latter mechanism that treatment with octreotide has been tried in a small number of patients with hypothalamic obesity, and it has yielded some encouraging results (Lustig et al. 2003b). Dextroamphetamine has also been used with some success in order to control weight gain in patients with obesity related to hypothalamic injury (Mason et al. 2002).

Childhood cancer survivors are at an increased risk of developing diabetes mellitus. In a report from the CCSS, survivors were almost twice as likely to report diabetes when compared with siblings. The major risk factors detected in this study were exposure to TBI, abdominal radiation, and alkylating agents (Table 1; Meacham et al. 2009). Disorders of glucose homeostasis have indeed been shown to occur in pediatric HSCT recipients, especially those treated with TBI. The primary abnormality seems to be increased resistance to insulin (Lorini et al. 1995, Taskinen et al. 2000, Hoffmeister et al. 2004, d’Annunzio et al. 2005, Neville et al. 2006, Baker et al. 2007, Chemaitilly et al. 2009). More studies are needed in order to elucidate the mechanisms through which TBI alters insulin sensitivity, and to define the best approach in managing this disorder.

Summary

Childhood cancer survivors have an increased risk of endocrine disease affecting many areas: hypothalamic–pituitary function, gonadal and reproductive function, thyroid function, body composition, and glucose homeostasis. The major risk factors include radiation therapy to key endocrine organs and exposure to alkylating agents. These endocrine abnormalities may evolve over many years. One of the future challenges will be to better characterize the role of genetic variability in the pathogenesis of these endocrine abnormalities. Early recognition and treatment can reduce morbidity and mortality in this vulnerable population. The importance of long-term surveillance of those at risk cannot be overemphasized.

Declaration of interest

Dr Sklar has served as a consultant for EMD Serono. Dr Chemaitilly has no financial conflicts to declare.

Funding

This review was not supported by a grant from any funding agency in the public, commercial, or not-for-profit sector.

References


Follin C, Thilén U, Ahrén B & Erfurth EM 2006 Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient


Grigg AP, McLaughlan R, Zajac J & Szer J 2000 Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). *Bone Marrow Transplantation* **26** 1089–1095.


Holm K, Nysom K, Brocks V, Hertz H, Jacobsen N & Muller J 1999 Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. *Bone Marrow Transplantation* **23** 259–263.


Ogilvy-Stuart AL & Shalet SM 1995 Growth and puberty after growth hormone treatment after irradiation for brain tumours. Archives of Disease in Childhood 73 141–146.


Sanders JE 2004 Endocrine complications of high-dose therapy with stem cell transplantation. Pediatric Transplantation 8 39–50.


Sklar C 1999 Reproductive physiology and treatment-related loss of sex-hormone production. Medical and Pediatric Oncology 33 2–8.


Sklar CA, Kim TH & Ramsay NKC 1984 Testicular function following bone marrow transplantation performed during or after puberty. Cancer 53 1498–1501.


